Market currently homogenizing the stock prices of the 3 vaccine companies
When MRNA's stock was trading in the mid $400s range towards the end of September, their total ;market cap value was worth about 10x higher than that of NVAX and today that difference is down to 7.2x, with the price difference down from about 77% in late September down to a manageable 33% today. In the case of BNTX the total market cap valuation difference has remained at about 4.4x greater than that of NVAX and the stock price gap has remained at around 37%. Once we start getting the approvals and begin to distribute vaccines to real people around the world, we should expect a significant improvement in the SP and total market cap valuation of NVAX. Am hopeful that the company is able to close the valuation gap which would entail having a SP higher than MRNA and BNTX. The SP upside potential is very promising assuming no major dislocations with their global manufacturing operations.